Cannabinoid Receptor 1 Antagonism Demonstrates High Therapeutic Potential for the Treatment of Primary Sclerosing Cholangitis

Cell Mol Gastroenterol Hepatol. 2022;13(4):1259-1260. doi: 10.1016/j.jcmgh.2022.01.009. Epub 2022 Feb 4.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Cholangitis, Sclerosing* / drug therapy
  • Humans
  • Receptors, Cannabinoid / therapeutic use

Substances

  • Receptors, Cannabinoid